TY - JOUR
T1 - Toward a universal influenza virus vaccine
T2 - Prospects and challenges
AU - Pica, Natalie
AU - Palese, Peter
PY - 2013/1/14
Y1 - 2013/1/14
N2 - Current influenza virus vaccines are annually reformulated to elicit protection by generating an immune response toward the virus strains that are predicted to circulate in the upcoming influenza season. These vaccines provide limited protection in cases of antigenic mismatch, when the vaccine and the circulating viral strains differ. The emergence of unexpected pandemic viruses presents an additional challenge to vaccine production. To increase influenza virus preparedness, much work has been dedicated to the development of a universal vaccine. Focusing on regions of viral proteins that are highly conserved across virus subtypes, vaccine strategies involving the matrix 2 protein, stalk domain of the hemagglutinin, and multivalent approaches have provided broad-based protection in animal models and showmuch promise. This review summarizes the most encouraging advances in the field with a focus on novel vaccine designs that have yielded promising preclinical and clinical data.
AB - Current influenza virus vaccines are annually reformulated to elicit protection by generating an immune response toward the virus strains that are predicted to circulate in the upcoming influenza season. These vaccines provide limited protection in cases of antigenic mismatch, when the vaccine and the circulating viral strains differ. The emergence of unexpected pandemic viruses presents an additional challenge to vaccine production. To increase influenza virus preparedness, much work has been dedicated to the development of a universal vaccine. Focusing on regions of viral proteins that are highly conserved across virus subtypes, vaccine strategies involving the matrix 2 protein, stalk domain of the hemagglutinin, and multivalent approaches have provided broad-based protection in animal models and showmuch promise. This review summarizes the most encouraging advances in the field with a focus on novel vaccine designs that have yielded promising preclinical and clinical data.
KW - DNA vaccines
KW - chimeric influenza viruses
KW - hemagglutinin
KW - heterologous protection
KW - stalk antibodies
UR - http://www.scopus.com/inward/record.url?scp=84873023493&partnerID=8YFLogxK
U2 - 10.1146/annurev-med-120611-145115
DO - 10.1146/annurev-med-120611-145115
M3 - Review article
C2 - 23327522
AN - SCOPUS:84873023493
SN - 0066-4219
VL - 64
SP - 189
EP - 202
JO - Annual Review of Medicine
JF - Annual Review of Medicine
ER -